Advanced search
1 file | 864.70 KB Add to list

Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients

(2018) PROSTATE. 78(5). p.336-342
Author
Organization
Abstract
Background: Noninvasive biomarkers to guide personalized treatment for castration-resistant prostate cancer (CRPC) are needed. In this study, we analyzed hypermethylation patterns of two genes (GSTP1 and APC) in plasma cell-free DNA (cfDNA) of CRPC patients. The aim of this study was to analyze the cfDNA concentrations and levels of the epigenetic markers and to assess the value of these biomarkers for prognosis. Methods: In this prospective study, patients were included before starting new treatment after developing CRPC. The blood samples were collected prior to start of the treatment and at three time points thereafter. cfDNA was extracted from 1.5mL of plasma and before performing a methylation-specific PCR, bisulfate modification was carried out. Results: The median levels of cfDNA, GSTP1, and APC copies in the baseline samples of CRPC patients (n=47) were higher than in controls (n=30). In the survival analysis, the group with baseline marker levels below median had significant less PCa-related deaths (P-values <0.02) and did not reach the median survival point. The survival distributions for the groups were statistically significant for the cfDNA concentration, GSTP1 and APC copies, as well as PSA combined with GSTP1+APC (P-values <0.03). Furthermore, there were strong positive correlations between PSA and marker response after starting treatment (P-values <0.04). Conclusions: In conclusion, this study showed the kinetics of methylated cfDNA (GSTP1 and APC) in plasma of CRPC patients after starting treatment. Furthermore, the value of the markers before treatment is prognostic for overall survival. These results are promising for developing a test to guide treatment-decision-making for CRPC patients.
Keywords
CPG ISLAND HYPERMETHYLATION, PLACEBO-CONTROLLED PHASE-3, TUMOR-CELLS, SERUM DNA, ABIRATERONE ACETATE, CLINICAL-RELEVANCE, PLUS PREDNISONE, DOUBLE-BLIND, PLASMA, CHEMOTHERAPY, APC, cell-free DNA, epigenetics, GSTP1, hypermethylation, prostate, cancer

Downloads

  • Hendriks 2018 Prostate.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 864.70 KB

Citation

Please use this url to cite or link to this publication:

MLA
Hendriks, Rianne J, Siebren Dijkstra, Frank P Smit, et al. “Epigenetic Markers in Circulating Cell-free DNA as Prognostic Markers for Survival of Castration-resistant Prostate Cancer Patients.” PROSTATE 78.5 (2018): 336–342. Print.
APA
Hendriks, R. J., Dijkstra, S., Smit, F. P., Vandersmissen, J., Van de Voorde, H., Mulders, P. F., van Oort, I. M., et al. (2018). Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients. PROSTATE, 78(5), 336–342.
Chicago author-date
Hendriks, Rianne J, Siebren Dijkstra, Frank P Smit, Johan Vandersmissen, Hendrik Van de Voorde, Peter FA Mulders, Inge M van Oort, Wim Van Criekinge, and Jack A Schalken. 2018. “Epigenetic Markers in Circulating Cell-free DNA as Prognostic Markers for Survival of Castration-resistant Prostate Cancer Patients.” Prostate 78 (5): 336–342.
Chicago author-date (all authors)
Hendriks, Rianne J, Siebren Dijkstra, Frank P Smit, Johan Vandersmissen, Hendrik Van de Voorde, Peter FA Mulders, Inge M van Oort, Wim Van Criekinge, and Jack A Schalken. 2018. “Epigenetic Markers in Circulating Cell-free DNA as Prognostic Markers for Survival of Castration-resistant Prostate Cancer Patients.” Prostate 78 (5): 336–342.
Vancouver
1.
Hendriks RJ, Dijkstra S, Smit FP, Vandersmissen J, Van de Voorde H, Mulders PF, et al. Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients. PROSTATE. 2018;78(5):336–42.
IEEE
[1]
R. J. Hendriks et al., “Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients,” PROSTATE, vol. 78, no. 5, pp. 336–342, 2018.
@article{8557773,
  abstract     = {Background: Noninvasive biomarkers to guide personalized treatment for castration-resistant prostate cancer (CRPC) are needed. In this study, we analyzed hypermethylation patterns of two genes (GSTP1 and APC) in plasma cell-free DNA (cfDNA) of CRPC patients. The aim of this study was to analyze the cfDNA concentrations and levels of the epigenetic markers and to assess the value of these biomarkers for prognosis. 
Methods: In this prospective study, patients were included before starting new treatment after developing CRPC. The blood samples were collected prior to start of the treatment and at three time points thereafter. cfDNA was extracted from 1.5mL of plasma and before performing a methylation-specific PCR, bisulfate modification was carried out. 
Results: The median levels of cfDNA, GSTP1, and APC copies in the baseline samples of CRPC patients (n=47) were higher than in controls (n=30). In the survival analysis, the group with baseline marker levels below median had significant less PCa-related deaths (P-values <0.02) and did not reach the median survival point. The survival distributions for the groups were statistically significant for the cfDNA concentration, GSTP1 and APC copies, as well as PSA combined with GSTP1+APC (P-values <0.03). Furthermore, there were strong positive correlations between PSA and marker response after starting treatment (P-values <0.04). 
Conclusions: In conclusion, this study showed the kinetics of methylated cfDNA (GSTP1 and APC) in plasma of CRPC patients after starting treatment. Furthermore, the value of the markers before treatment is prognostic for overall survival. These results are promising for developing a test to guide treatment-decision-making for CRPC patients.},
  author       = {Hendriks, Rianne J and Dijkstra, Siebren and Smit, Frank P and Vandersmissen, Johan and Van de Voorde, Hendrik and Mulders, Peter FA and van Oort, Inge M and Van Criekinge, Wim and Schalken, Jack A},
  issn         = {0270-4137},
  journal      = {PROSTATE},
  keywords     = {CPG ISLAND HYPERMETHYLATION,PLACEBO-CONTROLLED PHASE-3,TUMOR-CELLS,SERUM DNA,ABIRATERONE ACETATE,CLINICAL-RELEVANCE,PLUS PREDNISONE,DOUBLE-BLIND,PLASMA,CHEMOTHERAPY,APC,cell-free DNA,epigenetics,GSTP1,hypermethylation,prostate,cancer},
  language     = {eng},
  number       = {5},
  pages        = {336--342},
  title        = {Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients},
  url          = {http://dx.doi.org/10.1002/pros.23477},
  volume       = {78},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: